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Cu,Zn-superoxide dismutase (SOD1) is a protein involved in the antioxidant defense system of the body responsible for the 
dismutation of the superoxide anion. It contains two Cu and two Zn ions per molecule. As this protein is also involved in 
several diseases it is used in clinical diagnostics as biomarker, which requires the accurate and reliable determination of 
SOD1. Therefore, a candidate reference measurement procedure for the quantification of this protein in human erythrocytes 
was developed using species-specific isotope dilution mass spectrometry (IDMS), a method giving results traceable to the 15 
International System of Units (SI). The measurement procedure was validated with regard to a metrological point of view. 
Commercially available SOD1 was thoroughly characterized to be used as pure protein calibration standard in the IDMS 
approaches. Furthermore, 65Cu and 67Zn labeled SOD was produced to be used as spike material required for species-specific 
IDMS. Finally, SOD1 was quantified in human erythrocytes using both double and triple IDMS and a complete uncertainty 
budget for both approaches was estimated according to the Guide for the Expression of Uncertainty in Measurement (GUM). 20 
A calculated mass fraction of SOD1 with its associated expanded uncertainty of (63.94 ± 0.93) µg/g (n = 30) for double and 
(64.02 ± 0.96) µg/g (n = 30) for triple IDMS was obtained. 
Introduction 
Cu,Zn-superoxide dismutase (SOD1)1 is an homodimeric enzyme which contains a closely spaced non-covalently bound Cu 
and Zn ion pair2,3 and has a molecular mass of about 31800 g/mol for the human species. It catalyzes the disproportionation 25 
of the superoxide anion (O2
-) into oxygen (O2) and hydrogen peroxide (H2O2).
4 Responsible for the enzymatic activity is the 
Cu ion as the disproportionation of O2
- is driven by the [Cu(II)/Cu(I)] ion redox cycle.3 Besides a single disulfide bond and a 
complex network of hydogen bonds, the Zn ion accounts for the great stability of the SOD1. The enzymatic activity is linked 
to the Cu bound to the protein. The involvement of SOD1 in preventing oxidative stress can be used as bioindicator for 
environmental impact assessments.5 Additionally, the protein plays a role in medical diagnostics. SOD1 activity is known to 30 
decrease in malignant lymphoma,6 chronic alcoholism7 and medullar carcinoma,8 its activity is increased in leukemia.9 It can 
be used as prenatal marker for Down’s syndrome10 and is involved in neurodegenerative diseases such as Alzheimer’s 
disease.11 Furthermore, it is a potential marker for gastric cancer.12 When results from the quantitative determination of 
SOD1 are used for clinical diagnostics, it is of great importance that the results of the protein quantification are comparable 
and reliable (inter- and intralaboratory).13 In routine or clinical laboratories immunoassays such as enzyme-linked 35 
immunosorbent assay (ELISA)14 or spectrophotometric assays15,16 are used to quantify SOD1, but there are no reference 
methods or materials available yet. Comparison of some of these methods led to large differences in the results, the limits of 
quantification (LODs) and the reproducibility.17 This shows that reference methods and materials are urgently required. None 
of these clinical assays is based on metrological principles and results are not traceable to the International System of Units 
(SI) as demanded by directives such as Directive 98/79/EC.18 Furthermore, no uncertainty budget according to the Guide for 40 
the Expression of Uncertainty in Measurement (GUM) was estimated for the quantification of SOD1 for these methods. 
Within the project HLT05, a reference method traceable to the SI19 was developed for the first time using species-specific 
double and triple isotope dilution mass spectrometry (IDMS) for the quantification via the Cu content of SOD1. By 
measuring the Cu containing portion of the SOD1, only the amount of active protein is quantified. Thus, the method can 
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serve as reference method of higher order for the routine measurements. The basic principle of IDMS is the change of the 45 
natural isotopic composition of a chosen element in the sample by the addition of a substance enriched in a minor isotope of 
the chosen element, called spike. For the double IDMS approach,20 a blend of a reference material with the spike, the 
reference spike blend, is prepared and both sample spike and reference spike blends are measured with ICP-MS. In the 
reference material, the analyte is well characterized and acts as back spike. A further approach recently developed is triple 
IDMS,21,22,23 in which additionally a second reference spike blend is prepared. This is especially recommendable when a 50 
spike material is used with a comparable low enrichment leading to a high uncertainty in the measurement of the isotope ratio 
of the spike material as this isotope ratio is canceled from the equation. A more detailed description of the advantages of 
triple IDMS is given by Vogl.21 Although the IDMS approach is well-established and accepted for elemental analysis,24 the 
application in elemental speciation, especially for metalloproteins, is still challenging.25 For the use of IDMS in speciation 
analysis there are two basic approaches: The first one is the species-unspecific IDMS also referred to as post-column 55 
IDMS,26,27 where the elemental spike is added to the analyte after sample preparation and separation. The second one is the 
species-specific IDMS.28 Here, the species-specific spike material is added to the sample as soon as possible before any 
sample preparation and separation which has the advantage that any losses or changes of the analyte during the sample 
preparation process can be compensated for. 
Commercially available SOD1 was characterized for the use as reference material and species-specific spike material was 60 
prepared from this. As proof of concept SOD1 was quantified in a human erythrocyte sample by species-specific double and 
triple IDMS and the results were compared. 
 
Experimental 
Material and Reagents 65 
All chemicals used were of analytical grade or better unless stated otherwise. High-purity deionized water (18 MΩcm, Merck 
Millipore, Darmstadt, Germany) was used for the preparation of buffers and solutions. The chemicals for the preparation of 
buffer and solvents include ammonia acetate (NH4Ac), tris(hydroxymethyl)methylamine (Tris, both purchased from Sigma-
Aldrich, St. Louis, USA), acetic acid, nitric acid, hydrochloric acid (HCl), potassium hydroxide (KOH, all purchased from 
Merck, Darmstadt, Germany), ethylenediaminetetraacetic acid (EDTA), guanidinium chloride (GndCl, both purchased from 70 
Carl Roth, Karlsruhe, Germany), sodium chloride (NaCl, J.T. Baker, Center Valley, USA) and potassium chloride (KCl, 
Fisher, Loughborough, UK). Furthermore, ethanol (Carl Roth) and chloroform (AppliChem, Darmstadt, Germany) were 
used. For the acitivity assay pyrogallol and diethylenetriaminepentaacetic acid (DTPA), purchased from BDH (Dorset, UK), 
were used. Polyacrylamide gel electrophoresis (PAGE) was performed with hand-cast native gels and with native tris-glycine 
buffer. Reagents were purchased from Carl Roth. SOD1 from bovine erythrocytes as well as from human erythrocytes were 75 
purchased from Sigma-Aldrich. External calibration was performed using Cu and Zn standard solutions (AccuTrace, Bryn 
Mawr, USA). 65Cu and 67Zn, which were used for isotopic labelling of the bovine SOD1 were from CK Gas Products 
(Hampshire, UK) with a certified isotopic abundance of 63Cu 0.8 % and 65Cu 99.2 % and 64Zn 0.38 %, 66Zn 0.33 % and 68Zn 
99.0 %. For labelling the human SOD1, 65Cu and 67Zn were obtained from Chemotrade (Leipzig, Germany) with a certified 
isotopic abundance of 63Cu 0.3 % and 65Cu 99.7 % as well as 64Zn 0.67 %, 66Zn 1.19 %, 67Zn 97 %, 68Zn 1.11 % and 70Zn 80 
< 0.02 %. Stock solutions of isotopically enriched Cu and Zn were prepared by dissolving the metal in concentrated 
subboiled nitric acid and diluted gravimetrically to an appropriate working solution. Human erythrocytes were obtained from 
the German Blood Bank (Braunschweig, Germany), the bovine erythrocytes were obtained from a local abbortoir (Aberdeen, 
UK). 
Instrumentation 85 
The IDMS measurements as well as the characterization of the potential reference material were accomplished with a 
hyphenated high performance liquid chromatography (HPLC)-ICP-MS system. The chromatographic separation was 
performed with an Agilent 1200 (Agilent Technologies, Santa Clara, USA) equipped with a degasser, a binary pump, a 
thermostated autosampler, a column oven and a diode array detector (DAD). The separation was achieved on a strong anion 
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exchange column (MonoQ 5/50 GL, GE Healthcare, Uppsala, Sweden). The coupling of the HPLC to the ICP-MS was 90 
realized with a PEEK capillary. The isotopes of interest were detected with a quadrupol ICP-MS system (Agilent 7700cx) in 
pulse-counting mode. Typical intrumental working conditions for HPLC and ICP-MS are summerized in ESI table 1. For the 
post-column IDMS measurements the mass flow of the isotopically enriched spike was monitored continuously using the 
balance Genius ME215S (Sartorius, Göttingen, Germany) applying a method improved by Swart et. al.29 The balance sent the 
mass reading to the data aquisition software SartoConnect provided by the manufacturer of the balance. To determine the 95 
molecular mass of the native protein electrospray ionisation (ESI)-MS was used. The measurements were performed on the 
quadrupole time-of-flight (TOF) MS micrOTOF-Q (Bruker Daltonics, Billerica, USA). It was used in a positive detection 
mode with an extended mass range from 300 - 3000 Da. The obtained spectra were deconvoluted with the Data Analysis 
software provided by the manufacturer. 
Characterization of commercial available SOD1 for the use as reference for double IDMS 100 
The identity of the purchased protein was verified with molecular MS (ESI-TOF-MS). The sample was separated on a 
reversed phase column (Jupiter300-C4, Phenomenex, Torrance, USA) using an Agilent 1200 HPLC system. To determine the 
purity of the prepared protein solutions concerning the Cu amount post-column IDMS was used. The isotopic composition of 
the used spike material was fully characterized with a sector-field ICP-MS in high resolution. Furthermore, the protein was 
determined by UV-Vis, which is integrated in the HPLC, at 259 nm and 280 nm. 105 
Preparation and characterization of isotopically enriched SOD1 
Three published methods were compared regarding their demetallation efficiency and the possibility to remetallate the 
apo-protein to produce the isotopically labelled SOD1. In method A, the protein was dialyzed against NH4Ac buffer at pH 
2.830 and in method B against NH4Ac buffer containg EDTA at pH 3.8,
31 whereas in method C the demetallation was 
performed using GndCl.32 For remetallation to the produced apo-SOD1, 68Zn was added in surplus, firstly, and 65Cu, 110 
secondly. Both the apo- and remetallated SOD1 as well as the native protein were characterized regarding metal content, 
protein integrity and activity.15 Further information about instrumentation and methods are given in the ESI. 
Determination of SOD1 in human erythrocytes using IDMS 
For homogenization all solutions, erythrocytes, reference stock solution and spike stock solution, were vortexed at r.t. for at 
least one hour before use. The stock solutions of reference material and spike material were diluted to a final concentration of 115 
0.025 mg/g (reference material) and 0.1 mg/g (spike material), respectively. The reference spike blends as well as the 
erythrocyte spike blends for the IDMS measurements were prepared gravimetrically and homogenized for about an hour at 
r.t. before further use. To precipitate the hemoglobin, a mixture of ethanol/chloroform (3:1) was added to the blends in the 
ratio of 1:1. The blends were shaken for 20 min and then centrifuged at 12000 rpm and 4 °C for 15 min. The supernatant was 
transferred to another tube and the residue was discarded. To remove the organic solvents, the blends were concentrated 120 
using MWCO centrifugal filters and the residues were brought to their final volume with water. Finally, the prepared blends 
were measured with HPLC-ICP-MS. Peak areas were integrated with MassHunter software from Agilent. The SOD amount 
in the erythrocytes was calculated using the equations for double IDMS and triple IDMS (equations are given in the results 
and discussion section). The expanded uncertainty for both approaches was estimated with the GUM workbench (Metrodata 
GmbH, Weil am Rhein, Germany). 125 
 
Results and discussion 
Characterization of commercial available SOD1 for the use as reference for double IDMS 
The identity of the purchased human SOD1 was checked by means of ESI-TOF-MS (data given in ESI figure 1). To exclude 
the occurance of protein impurities the protein was determined after separation by UV-vis. The column recovery was 130 
calculated to be (68.62 ± 0.90) % for SOD1 (n = 10) on the SAX column regarding the Cu content. A purity of > 80 % of the 
protein material by Biuret is stated by the manufacturer. To check this, the purity of the prepared protein solutions was 
determined by performing post column IDMS as developed by Heumann et. al.26 and optimized by Swart et. al.29, in which 
the isotopically enriched spike material is added continously to the effluent from the HPLC with a peristaltic pump via a T-
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piece. With the SartoConnect software the mass flow of the spike was recorded continously over the whole time of the 135 
chromatogram. The 63Cu isotope serves as reference isotope. In all measurements, the isotope ratios were corrected for mass 
bias by the determination of the correction factor K calculated by setting  the natural isotope ratio of a measured sample in 
relation to the “true” isotope ratio according to the International Union of Pure and Applied Chemistry (IUPAC). Protein 
solutions and spike solutions, which were added to the sample post-column, were prepared gravimetrically. The deployed 
masses were corrected for air buoyancy. To take into account the sample loss during the separation procedure the column 140 
recovery is considered in the calculation of the Cu mass fraction of the sample. The used equation is given in the ESI.29 For 
the used SOD1 material, a Cu mass fraction of (0.290 ± 0.014) µg/g was calculated (n = 20), which corresponds to a SOD1 
amount of (0.073 ± 0.004) mg/g. The purity of the purchased material and its estimated uncertainty was found to be 
(72.80 ± 4.9) % with regard to the Cu amount. The uncertainty budget was estimated with the GUM workbench as extended 
uncertainty (k = 2).  145 
Production of enriched SOD1 
The first step of the SOD1 spike production is the demetallation followed by remetallation with isotopically enriched metals 
(a general scheme is given in figure 1). Due to the high stability of the Cu and Zn bonds in SOD1, relatively harsh conditions 
are required for demetallation, which may lead to irreversible changes of the secondary structure. Three methods are used 
predominantly in the literature and these were tested for the preparation of bovine SOD1 spike material (*SOD1) and 150 
compared to each other to get a spike fit for purpose in species-specific IDMS. One of the first methods for the removal of 
both Cu and Zn, was the treatment of the protein with EDTA at low pH (called method B in the present work).33,34,35 Another 
method includes the use of even lower pH but omits the use of EDTA (method A).30 One method which does not expose the 
enzyme to low pH, uses the denaturating ability of GndCl and EDTA as complexing agents (method C).36,37,32 Demetallation 
and remetallation efficiency as well as isotope enrichment was determined by SEC-ICP-MS (ESI table 3 and ESI figures 3 155 
and 4). The correct incorporation of the metals into their native sites is checked by performing native gel electrophoresis and 
activity assay (ESI table 3 and ESI figure 2). To ensure that the produced *SOD1 is stable in the biological matrix, the spike 
was added to bovine erythrocytes and the isotope ratios were measured (ESI figures 5 and 6). Compared to the other two 
methods *SOD1 produced according to method B has the highest remetallation efficiency and isotopic enrichment. Dimeric 
protein structure as well as activity is restored nearly completely. Furthermore, *SOD1 is stable when added to biological 160 
samples, which shows that method B is the most suited method for producing species-specific spike material.38,39  
Quantification of SOD1 in human erythrocytes using species-specific double and triple IDMS 
Bovine SOD1 spike showed different stability in samples of human origin and a different retention time compared to human 
SOD and is, therefore, not suitable as spike for human erythrocyte lysate as shown by Nuevo-Ordonez et. al.39 Hence, for the 
determination of SOD1 in human erythrocyte lysate, a spike was prepared from commercial human SOD1 following method 165 
B. A chromatogram of the produced human *SOD1 is shown in figure 1. To determine if the human *SOD1 is applicable for 
the use in species-specific IDMS, the stability of the spike in human erythrocytes was tested over a time period of 48 h and 
found to be satisfactory (ESI figure 7), which makes it fit for use in double and triple IDMS experiments. The advantage in 
performing double species-specific IDMS is that, compared to single species-specific IDMS,39 the purity of the used species-
specific spike has not to be known as it is canceled from the equation when using exact matching IDMS. However, a key step 170 
in double IDMS measurements is the characterization of the purchased protein to be used as reference. The sample spike 
blends (bx) and the reference spike blends (bz) were prepared three times each independently on three different days. Each 
blend was measured ten times in a bracketing sequence. For the double IDMS experiments, the reference as well as the 
erythrocyte sample were mixed with the isotopically enriched spike material to result in an isotope ratio of 65Cu/63Cu of 
approximately 1:1 (figure 2). For all measurements, the isotope ratios were corrected for mass bias. Equation 220 was used for 175 
calculation of the SOD1 amount. Meanings of the used symbols are described in table 1. 
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The deployed masses of reference solution, spike solution and samples were corrected for air buoyancy. The calculated 180 
SOD1 mass fraction in the erythrocyte sample as well as the estimated expanded uncertainty is listed in table 2. As shown in 
table 3, the main contributions to the uncertainty were found to be the uncertainty of the purity of the used reference (wpur) 
and the measured isotope ratios in the sample spike blend (Rbx) and the reference spike blend (Rbz). For the double IDMS 
measurements the variation of the individual results and the average are shown in figure 3A. For triple IDMS the same 
erythrocyte sample was mixed with *SOD1 to result in an approximated 1:1 ratio. Unlike for double IDMS, the triple IDMS 185 
approach requires two reference spike blends, both with a slightly different final isotope ratio but both close to 1:1. The final 
isotope ratio 65Cu/63Cu was chosen to be approximately 0.9 for the first reference spike blend (Rbz1) and approximately 1.1 
for the second reference spike blend (Rbz2). In this approach the sample spike blend (bx) and reference spike blends (bz1, 
bz2) were prepared three times independently and on three different day. While bx is measured ten times, bz1 and bz2 were 
measured six and five times, respectively, in a bracketing sequence (means bz1_1. bx_1, bz2_1, bx_2, bz1_2, bx_3, bz2_2, 190 
bx_4, bz1_3, bx_5, bz2_3,...). The deployed masses during the preparation of the blends were corrected for air buoyancy. 
Equation 323 was used to calculate the SOD1 amount in the sample following triple IDMS approach. Meanings of the used 
symbols are described in table 1. 
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The calculated SOD1 amount in erythrocytes and the appropriate expanded uncertainty given by the triple IDMS approach is 
shown in table 2. Major contributions to the uncertainty were found to be the measured isotope ratios in bx followed by the 
measured isotope ratios in the reference spike blends and the purity of the reference used as shown in table 3. The variation 
of the individual results and the average of the triple IDMS measurements are shown in figure 3B. In comparison to double 200 
IDMS the advantage of triple IDMS is, that the isotopic composition of the spike (Ry) has not to be determined as it is 
cancelled from the equation. This is offset by a slightly higher workload due to the preparation of a second reference spike 
blend and an increased measurement time. The results obtained from the double IDMS and triple IDMS approach for the 
determined human erythrocyte sample fit together very well within the estimated uncertainty which is also confirmed by the 
t-test as the empirical t-value is smaller than the critical t-value (0.502 < t < 2.776, α = 0.05). The high precision of the 205 
applied methods is pointed out by the achieved estimated expanded uncertainty of 1.45 % and 1.50 %, respectively. This 
demonstrates the usefulness of species-specific double and triple IDMS to provide reference values for clinical laboratories as 
there are no reference methods or materials for SOD1 available yet. 
 
Conclusion 210 
Two methods based on double and triple IDMS were applied for the precise quantification of SOD1 in human erythrocytes. 
Purchased human SOD1 was characterized using single post-column IDMS, UV-Vis and ESI-TOF-MS before use as a 
reference, which is the key component in IDMS. Furthermore, species-specific spike material was produced and 
characterized. A detailed comparison study of three methods published in the literature showed that using low pH and EDTA 
is the most suitable method for demetallation in the SOD1 spike preparation procedure. Final quantification of SOD1 in a real 215 
sample of human erythrocytes via double and triple IDMS shows a good agreement for the results of both methods within the 
expanded uncertainty. A complete uncertainty budget was estimated using the GUM workbench. The expanded uncertainty 
(with k = 2) of below 2 % for both approaches demonstrates the high precision of the applied methods. The developed 
methods enable traceability of the results to the SI and can, therefore, be used as reference methods of higher order for 
routine analysis methods in clinical laboratories as required by the European in vitro diagnostica directive (Directive 220 
98/79/EC) for the use of in vitro diagnostica in samples of human origin.18 Furthermore, there is the chance to characterize 
SOD1 in a biological matrix for the use as reference material for validating quantification methods in medical routine 
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laboratories. Thus, providing reference values to clinical laboratories will help to make the results of different routine 
measurement procedures more comparable. As SOD1 is an important marker amongst others for neurodegenerative diseases 
such as Alzheimer’s disease or amyothrophic lateral sclerosis, where the concentration is much lower (0.5 µg/g in 225 
cerebrospinal fluid40) than in erythrocytes, in the future perspectives strategies for the enrichment of SOD1 have to be 
developed so that quantification by species-specific IDMS can be applied for this purpose. 
 
Acknowledgement 
This research was untertaken within the EMRP project HLT05. The EMRP was jointly funded by the EMRP participating 230 
countries within EURAMET and the European Union. We gratefully acknowledge support by the Braunschweig 
International Graduate School of Metrology B-IGSM.  
 
 
 235 
Figure 1. Chromatogram of produced human SOD1 spike material. 
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B 
  
Figure 2. A) sample spike blend and B) reference spike blend prepared for the use in double IDMS measurements. 
 
Table 1. Meaning of the symbols used in the equations (1) – (3). 
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wx, wz g/kg mass fraction of Cu in sample x and reference z, resp. 
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Rx, Ry, Rz mol/mol isotope amount ratio of spike and reference isotope 
(65Cu/63Cu) in sample x, spike y and reference z, resp. 
Rbx, Rbz, Rbz1, Rbz2 mol/mol isotope amount ratio of spike and reference isotope 
(65Cu/63Cu) in blends bx (sample x + spike y) and blends bz, 
bz1 and bz2 (reference z, z1, z2 + spike y), resp. 
mx, mz, mz1, mz2, myx, myz, myz1, myz2 g masses of sample x, references z, z1, z2 and spike y solutions, 
resp. 
 240 
Table 2. Calculated SOD1 amount in a human erythrocyte sample and the appropriate expanded uncertainty for species-
specific double and triple IDMS approach. 
 SOD1 amount in erythrocytes 
in µg/g 
expanded uncertainty (k = 2) 
in µg/g 
expanded uncertainty (k = 2) 
in % 
double IDMS 63.94 0.93 1.45 
triple IDMS 64.06 0.96 1.50 
 
Table 3. Major contributions to the uncertainty of the amount of SOD1 in erythrocytes using species-specific double and 
triple IDMS, resp. 245 
 double IDMS 
in % 
triple IDMS 
in % 
wpur 71.7 70.4 
Rbx 15.3 15.6 
Rbz 10.6 - 
Rbz2 - 11.4 
 
A B 
  
Figure 3. Variation of the individual results for A) double IDMS measurements and B) triple IDMS measurements. The error 
bars represent the expanded uncertainty (k = 2) of the single values. The average with its estimated uncertainty is illustrated 
in red. 
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